Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients

The rapid advancement in the development of therapeutic proteins, including monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), has created a novel mechanism to selectively deliver highly potent cytotoxic agents in the treatment of cancer. These agents provide numerous benefits compare...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucas, Andrew T., Robinson, Ryan, Schorzman, Allison N., Piscitelli, Joseph A., Razo, Juan F., Zamboni, William C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6640706/
https://www.ncbi.nlm.nih.gov/pubmed/31544809
http://dx.doi.org/10.3390/antib8010003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6640706/
https://www.ncbi.nlm.nih.gov/pubmed/31544809
http://dx.doi.org/10.3390/antib8010003

Ejemplares similares